Issue link: https://www.e-digitaleditions.com/i/1532011
30 February 2025 Inhalation 38. Carvalho, T.C., et al., e function and perfor- mance of aqueous aerosol devices for inhalation ther- apy. J Pharm Pharmacol, 2016. 68(5): p. 556-578. 39. Forbes, I.I., Human airway epithelial cell lines for in vitro drug transport and metabolism studies. Pharm Sci Technol Today, 2000. 3(1): p. 18-27. 40. Selo, M.A., et al., In vitro and ex vivo models in inhalation biopharmaceutical research—Advances, challenges and future perspectives. Adv Drug Deliv Rev, 2021. 177: p. 113862. 41. Baldassi, D., et al., Air-liquid interface cultures of the healthy and diseased human respiratory tract: Promises, challenges and future directions. Adv Nanobiomed Res, 2021. 1(6). 2000111. 42. Gerckens, M., et al., Generation of human 3D lung tissue cultures (3D-LTCs) for disease modeling. J Vis Exp, 2019(144). 43. Preuss, E.B., et al., e challenge of long-term cultivation of human precision-cut lung slices. Am J Pathol, 2022. 192(2): p. 239-253. 44. Yamada, S., et al., SARS-CoV-2 induces barrier damage and inflammatory responses in the human iPSC-derived intestinal epithelium. J Pharmacol Sci, 2022. 149(3): p. 139-146. 45. Goris, K., et al., Differential sensitivity of differ- entiated epithelial cells to respiratory viruses reveals different viral strategies of host infection. J Virol, 2009. 83(4): p. 1962-1968. 46. Squires, S.D., et al., e impact of non-infection pandemic stress on depression and anxiety severity: Investigating mediation by intrusive and deliberate rumination. J Affect Disord, 2022. 310: p. 291-295. Joschka T. Müller, PhD Student, Pharmaceutical Tech- nology and Biopharmaceutics, Department of Phar- macy, Ludwig-Maximilians-University München, Munich, Germany. omas Michler, PD Dr. med., Medical Specialist and Research Group Leader, Insti- tute of Laboratory Medicine, LMU University Hos- pital, Ludwig-Maximilians-University München, Munich, Germany. Olivia M. Merkel, Prof. Dr. rer. nat., Professor of Drug Delivery (Chair), Pharma- ceutical Technology and Biopharmaceutics, Depart- ment of Pharmacy, Ludwig-Maximilians-University München, Munich, Germany and Center for Nano- Science Munich (CeNS), Munich, Germany and Clus- ter for Nucleic Acid erapeutics Munich (CNATM), Munich, Germany, olivia.merkel@lmu.de, (corre- sponding author). 22. Merkel, O.M., et al., Quo vadis polyplex? J Con- trol Release, 2014. 190: p. 415-423. 23. Jin, Y., et al., Role of hydrophobic modification in spermine-based poly(beta-amino ester)s for siRNA delivery and their spray-dried powders for inhalation and improved storage. Biomacromolecules, 2024. 25(7). 24. Kromer, A.P.E., et al., Design of experiments grants mechanistic insights into the synthesis of spermine-containing PBAE copolymers. ACS Appl Mater Interfaces, 2024. 16(29): p. 37545-37554. 25. Jin, Y., et al., Synthesis and application of spermine- based amphiphilic poly(beta-amino ester) s for siRNA delivery. Nanoscale Adv, 2023. 5(19): p. 5256-5262. 26. Winkeljann, B., et al., Engineering poly- and micelleplexes for nucleic acid delivery--A reflection on their endosomal escape. J Control Release, 2022. 353: p. 518-534. 27. Dominska, M., et al., Breaking down the barri- ers: siRNA delivery and endosome escape. J Cell Sci, 2010. 123(Pt 8): p. 1183-1189. 28. Merkel, O.M., et al., Nonviral pulmonary delivery of siRNA. Acc Chem Res, 2012. 45(7): p. 961-970. 29. Cryan, S.A., et al., In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev, 2007. 59(11): p. 1133-1151. 30. Lam, J. K., et al., Pulmonary delivery of therapeu- tic siRNA. Adv Drug Deliv Rev, 2012. 64(1): p. 1-15. 31. Duncan, G.A., et al., e mucus barrier to inhaled gene therapy. Mol er, 2016. 24(12): p. 2043-2053. 32. Lai, D., et al., SARS-CoV-2 N protein triggers acute lung injury via modulating macrophage activa- tion and infiltration in in vitro and in vivo. J Inflamm Res, 2023. 16: p. 1867-1877. 33. Cone, R.A., Barrier properties of mucus. Adv Drug Deliv Rev, 2009. 61(2): p. 75-85. 34. Duncan, J.E., et al., Pulmonary surfactant inhib- its cationic liposome-mediated gene delivery to respi- ratory epithelial cells in vitro. Hum Gene er, 1997. 8(4): p. 431-438. 35. Lebhardt, T., et al., Polymeric nanocarriers for drug delivery to the lung. J Drug Deliv Sci Technol, 2010. 20(3): p. 171-180. 36. Knoch, M., et al., e customised electronic nebuliser: A new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv, 2005. 2(2): p. 377-390. 37. Agu, R.U., et al., e lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res, 2001. 2(4): p. 198-209.